The KIT receptor tyrosine kinase is normally highly expressed in myeloid cells and mast cells and promotes growth through interaction with its ligand, stem cell factor. 1 Activating kinase domain point mutations in KIT at codon 816 in exon 17, predominantly Asp816Val and less commonly Asp816Phe, are highly associated with mast cell disorders (MCD) and result in ligand-independent kinase signaling. 2, 3 A number of studies have shown that KIT mutations can be present in a variety of cell lineages 4 and this results in a spectrum of systemic MCD with associated hematological clonal non-mast cell lineage disease (AHNMCD) that have differing clinical behavior. 5, 6 Mast cells in bone marrow (BM) in MCD can be easily enumerated by direct microscopic examination, with the aid of mast cell tryptase or CD117 immunostaining, or by flow cytometric analysis (e.g. gating on CD117 þ CD25 þ CD2 À mast cells). However, MCD with AHNMCD is not as easily recognized. We show here that quantitative pyrosequencing and mutation-specific quantitative polymerase chain reaction (qPCR) assays for the detection of KIT codon 816 mutation can be used to highlight the mixed and pure forms of MCD to better aid in disease classification.
Pyrosequencing is a DNA sequencing-by-synthesis method developed for single-nucleotide polymorphism analysis 7 that we have adapted here to provide quantitation of the levels of mutated and unmutated product at codon 816 of KIT. For this study, genomic DNA was isolated from BM core biopsy and/or BM aspirate samples from 39 patients with morphological evidence of MCD using WHO criteria, 6 and subjected to pyrosequencing of KIT exon 17. The majority of cases (n ¼ 34)
were also analyzed by direct sequencing using the standard dideoxy-chain termination (Sanger) method. Cases that were negative for codon 816 KIT mutation were also assessed using a D816V mutation specific-probe TaqMan real-time quantitative PCR method. To increase the sensitivity of analysis in BM biopsy material, mast cell clusters, identified on parallel hematoxylin and eosin-stained section, were manually dissected from formalin-fixed paraffin-embedded sections before DNA extraction and PCR amplification in a subset of cases.
The pyrosequencing genomic PCR assay assessed exon 17 of KIT between codons 815 and 822, with a sequencing dispensation order maximized for interrogation of codon 816. PCR (forward 5 0 -TCATGGTCGGATCACAAAGAT, reverse 5 0 -Biotin-CAGGACTGTCAAGCAGAGAATGG) was done for 35 cycles at 941C for 30 s, 561C for 90 s, and 721C for 45 s, followed by purification of product over streptavidin sepharose beads and sequencing using a third primer (5 0 -TGATTTTGGTCTAGCCAG) performed on a PSQ HS 96 Pyrosequencer (Biotage, Uppsala, Sweden). PCR were run in duplicate and quantification of the ratio of codon 816 mutated versus unmutated PCR product was determined by averaging the peak heights. To optimize the relative quantitative features of the pyrosequencing assay, PCR conditions were optimized to allow as small a number of amplification cycles as possible to generate adequate product for sequence determination. Assuming most tumor cells will have one normal and one mutant allele of KIT, the percentage of mutated PCR product would be expected to be half as high as the number of tumor cells. In cases with low level of mutated PCR product, qPCR was also performed using KIT-816V (mutated) and KIT-816D (unmutated) FAM dye-labeled MGB probes in separate PCRs using the TaqMan method on a 7900HT detection system (Applied Biosystems, Foster City, CA, USA).
Thermocyling conditions were 951C for 10 min followed by 40 cycles of 951C for 15 s and 611C for 1 min. The sensitivity of each assay was determined by serially diluting DNA with KIT-816V into DNA obtained from cells with umutated KIT. The sensitivity established by this technique was 5% mutated cells for pyrosequencing, 1% for qPCR and 20% for direct Sanger sequencing.
Using the exon 17 pyrosequencing assay, we tested 74 samples (29 BM biopsies, 45 BM aspirates) from 39 patients with morphologic evidence of MCD. The levels of marrow involvement determined by mast cell number in a 400-cell aspirate differential or semi-quantification of the area occupied by mast cell aggregates in a parallel section of the biopsy varied from 1 to 60% but was below 5% in 21 of the cases. Codon 816 KIT mutation was detected in 16 of 39 patients (41%) by pyrosequencing and included D816V in 15 cases and D816F in one. There was a significant difference between detection frequency of KIT mutation in those cases which had mast cell counts of at least 10% (12/16, 75%) versus those below 10% mast cell counts (4/23, 17%) (P ¼ 0.001); direct sequencing by the Sanger method correlated with pyrosequencing in all samples with greater than 15% mast cells but failed to detect unequivocally mutations below that level. KIT mutation was not unequivocally detected by pyrosequencing in any case where the mast cell counts were below 5% establishing a lower limit of sensitivity of detection of this assay. Pyrogram peak heights corresponding to the mutated product which were below 5%, were considered equivocal and those cases were subjected to further analysis with mutation-discrimination qPCR and detected D816V KIT mutation in five additional patients for an overall mutation incidence of 54% for all MCD cases. There were no discordances between qPCR and pyrosequencing when mast cell counts were above 5%. Figure 1 shows the correlation between the numbers of mast cells and myeloid cells in BM aspirate samples and the levels of mutated PCR product determined in the 16 cases with KIT codon 816 mutations detected by pyrosequencing. Marrow aspirate myeloid cell counts included neutrophils, metamyelocytes, myelocytes, promyelocytes, eosinophils and basophils. In five cases (#10, 13-16), the amount of codon 816 mutated PCR Figure 1 Correlation of levels of KIT D816V mutation with myeloid cell counts as an aid in classification of the type of mast cell disorder. Mast cell and combined non-mast cell myeloid cell counts were done on BM aspirates, and compared to percentage of KIT mutated PCR product detected in a parallel BM aspirate sample. Final diagnoses listed in groups 1 (cases 1-6), 2 (cases 7-10) and 3 (cases 11-16) were based on a review of all pathological material and clinical features. Letters to the Editor products was significantly higher (greater than 2-fold) than the morphologic mast cell counts, which suggested the presence of KIT mutation in non-mast cell components. Table 1 summarizes the demographics, BM myeloid cell counts, KIT mutation levels and final disease classification. Review of clinical features and pathological material revealed coexisting AHNMCD in all five discordant cases. Among the remaining 11 cases in which percentage of mutated KIT PCR product was roughly equal to or less than the number of mast cells, three had associated mild eosinophilia, two had associated CMML and the rest were morphologically consistent with pure MCDs. There was striking female predominance among the pure MCD and MCD with isolated eosinophilia cases (9 of 10) compared to the male predominance in MCD with AHNMCD cases (6/6 male, Po 0.002). For all 39 patients in the study, KIT mutation was detected much more frequently in MCD with ANMHD compared with those cases in which KIT mutation was not detected by either pyrosequencing or D816V qPCR (1/26, 1 CMML).
We show here that a routine quantitative pyrosequencing assay for KIT codon 816, while not sensitive enough to detect mutation in unsorted samples of MCD with minimal (o5%) marrow involvement, can readily highlight those cases of MCD associated with an associated KIT mutation-bearing myeloid or eosinophilic component. The quantitative nature of pyrosequencing, however, provides a rapid method to help recognize cases of MCD-AHNMD and differentiate them from pure MCD. Given the differential sensitivity of MCD with different molecular abnormalities to kinase inhibitors, quantitative molecular classification methods for KIT mutation detection will also be essential to establish the molecular correlates of response of MCD subtypes to novel targeted therapeutic agents. Lenalidomide (Revlimid, Celgene) is an immunomodulatory agent with both erythropoetic and cytogenetic remitting activity in patients with primary myelodysplastic syndrome (MDS) associated with interstitial deletion of chromosome 5q. MDS secondary to chemotherapy or ionizing radiation is historically associated with an aggressive natural history and unfavorable prognosis with resistance to standard therapeutic agents. 1 Here we report two patients with secondary MDS and deletion 5q who achieved hematologic or cytogenetic responses following treatment with lenalidomide.
In the first case, a seventy-four-year-old male with secondary MDS was initially diagnosed in June 1999 with adenocarcinoma of the gastroesophageal junction. He underwent esophagectomy with gastric pull through and surgical staging of T3 N1 M0 disease (six of nine lymph nodes involved). He received 45 Gy post-operative radiotherapy and aggressive local regional 
